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Manpreet Kaur, Shilpi Sachdeva, Onkar Bedi, Tavleen Kaur and Puneet Kumar*The original version of this article [1] unfortunately con-
tained mistakes to the figure legends and was missing
Figure 7 (Fig. 1 here). The corrected legends are as
follows:
Fig. 1 Experimental Protocol design.
Fig. 2 Effect of NaHS on blood glucose level in STZ
treated rats. aP < 0.05 versus vehicle treated, bP < 0.05
versus [STZ (45)] treated group, cP < 0.05 versus
[STZ (45) + NaHS (10)] treated group, dP < 0.05 versus
[STZ (45) +NaHS (30)] treated group. STZ= Streptozotocin,
NaHS = Sodium hydrosulphide, LOS = Losartan, DL-p =
DL-propargylglycine.
Fig. 3 Effect of NaHS and losartan on Lipid Peroxida-
tion in STZ treated rats. aP < 0.05 versus vehicle treated,
bP < 0.05 versus [STZ (45)] treated group, cP < 0.05 ver-
sus [STZ (45) + NaHS (10)] treated group, dP < 0.05 ver-
sus [STZ (45) + NaHS (30)] treated group, eP < 0.05
versus [STZ (45) + LOS (5)] treated group. STZ =
Streptozotocin, NaHS = Sodium hydrosulphide, LOS =
Losartan, DL-p = DL-propargylglycine.
Fig. 4 Effect of NaHS and losartan on Reduced
Glutathione in STZ treated rats. aP < 0.05 versus* Correspondence: punnubansal79@gmail.com
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group, cP < 0.05 versus [STZ (45) + NaHS (10)]
treated group, dP < 0.05 versus [STZ (45) + NaHS
(30)] treated group, eP < 0.05 versus [STZ (45) + LOS
(5)] treated group. STZ = Streptozotocin, NaHS =
Sodium hydrosulphide, LOS = Losartan, DL-p =
DL-propargylglycine.
Fig. 5 Effect of NaHS and losartan on Nitrite in STZ
treated rats. aP < 0.05 versus vehicle treated, bP < 0.05
versus [STZ (45)] treated group, cP < 0.05 versus [STZ
(45) + NaHS (10)] treated group, dP < 0.05 versus [STZ
(45) + NaHS (30)] treated group, eP < 0.05 versus [STZ
(45) + LOS (5)] treated group. STZ = Streptozotocin,
NaHS = Sodium hydrosulphide, LOS = Losartan, DL-p =
DL-propargylglycine.
Fig. 6 Effect of NaHS and losartan on MABP in STZ
treated rats. aP < 0.05 versus vehicle treated, bP < 0.05
versus [STZ (45)] treated group, cP < 0.05 versus [STZ
(45) + NaHS (10)] treated group, dP < 0.05 versus [STZ
(45) + NaHS (30)] treated group, eP < 0.05 versus [STZ
(45) + LOS (5)] treated group. STZ = Streptozotocin,
NaHS = Sodium hydrosulphide, LOS = Losartan, DL-p =
DL-propargylglycine.distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Kaur et al. Journal of Diabetes & Metabolic Disorders  (2015) 14:80 Page 2 of 2The missing figure can be found below, with the
correct figure legend:Fig. 1 Hemotoxylin-Eosin stained longitudinal section of kidneys (10×). a Normal control, b STZ treated group (45), c NaHS (30), d DL-p (10) +
NaHS (30), e LOS, f NaHS (10) + Losartan (5)Received: 7 October 2015 Accepted: 8 October 2015
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